Oxley and Opie's invention, the Synchron Switch™, is an endovascular brain implant designed to record or stimulate the brain or nerves from within th...
Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP...
Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...
“Resolian merges expertise from Alliance Pharma and Drug Development Solutions — two leading providers of bioanalysis and analytical sciences &...
The first diagnostic test for long COVID is now available to patients across Australia. The test can help physicians diagnose long COVID by differentiating...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced positive results today from the pedia...
PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Austr...
As a sponsor of the event, The Clinician team will be showcasing their healthcare solutions on the exhibition floor at booth F18 and will be hosting a dedi...
Located in the prestigious SAHMRI building in Adelaide, SAGC is a nationally accredited genomics facility that supports research nationally and internation...
The grant has been awarded by the Australian Government's National Health and Medical Research Council (NHMRC), and will be matched by the South Australian...
Dedicaid's core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from a...
Expanded facility to manufacture mRNA-based therapies and vaccines Researchers at the University of Adelaide will address the design and manufacturi...
In April 2022, Telix secured the exclusive worldwide rights to develop and commercialise radiolabelled forms of olaratumab for the diagnosis and treatment ...
© 2025 Biopharma Boardroom. All Rights Reserved.
